Drug Trial Radar · NCT07864701
Study of JMBI-001 in Patients With MYC-Positive Advanced Cancers
Last checked: Nov 20, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
150
Planned (sponsor's estimate)
Start
Oct 2026
Primary completion
Jun 2029
Study completion Jun 2030
Sponsor
- Lead sponsor
- Chengdu Anticancer Bioscience, Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Peking University Cancer Hospital & Institute
- First posted
- Oct 8, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Evaluate the safety and tolerability of JMBI-001 in adults with MYC-positive advanced cancers.
Conditions
- Advance Solid Tumors
- Lymphoma, Non-Hodgkin
Interventions
JMBI-001 TabletsDrug
JMBI-001 will be administered orally once daily on an empty stomach for 4 consecutive days, followed by 3 days without treatment, in repeated 21-day treatment cycles. Dose levels will be determined according to the study protocol.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase Ia: dose-limiting toxicities (DLTs)Time frame: Cycle 1, Days 1-21 after the first dose (21-day DLT assessment period)
- Phase Ia: maximum tolerated dose (MTD)Time frame: At completion of Phase Ia dose escalation, after completion of the 21-day DLT assessment period for each dose cohort, up to approximately 15 months after the first participant receives the first dose.
- Phase 1a:recommended dose for expansion (RDE)Time frame: At completion of Phase Ia dose escalation, after review of DLTs and other available safety data, up to approximately 15 months after the first participant receives the first dose.
- Phase Ia/Ib: adverse events (AEs), serious adverse events (SAEs)Time frame: From informed consent, during each 21-day treatment cycle, at the end-of-treatment visit (within 7 days of treatment discontinuation), and through 30 days after the last dose or until new anticancer therapy starts, whichever occurs first
- Phase Ib: determination of the recommended Phase II dose (RP2D)Time frame: From the first dose administered to the first participant in Phase Ia through completion of Phase Ib dose expansion, up to approximately 27 months.
- Phase II: Objective response rate (ORR)Time frame: From baseline until disease progression, initiation of new anticancer therapy, or withdrawal, assessed up to approximately 24 months.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking University Cancer Hospital & Institute
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.